PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Milsaperidone→

Milsaperidone PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
501373-88-2
Molecular formula
C24H29FN2O4
Molecular weight
428.5 g/mol
Drug class
Atypical antipsychoticpiperidinyl-benzisoxazole derivative
Mechanism of action
The mechanism of action in schizophrenia and acute manic or mixed episodes of bipolar I disorder is unknown. Clinical efficacy may be mediated through a combination of dopamine D2 and serotonin 5-HT2 receptor antagonism. Milsaperidone and iloperidone rapidly interconvert in vivo; the receptor-binding profile is similar to iloperidone.
Indications / reported uses
  • Treatment of schizophrenia in adults under the US BYSANTI indication (initial US approval 2026)
  • Acute treatment of manic or mixed episodes associated with bipolar I disorder in adults under the US BYSANTI indication; do not infer a distinct mechanism from its pharmacodynamic binding profile

Sources: US FDA prescribing information — BYSANTI (milsaperidone), 2026 · NLM DailyMed — BYSANTI (milsaperidone) · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Milsaperidone PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Milsaperidone Permitted Daily Exposure (PDE) report (the Milsaperidone PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Milsaperidone Occupational Exposure Limit (OEL) report (the Milsaperidone OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.